Keratoacanthoma - I-Keratoacanthoma
☆ AI Dermatology — Free Service
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Ngokwesiqhelo, i-Keratoacanthoma (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) lithumba eliqhelekileyo lolusu elaziwa ngokukhula ngokukhawuleza kunye nokuhla kwayo ngokwayo. Ngokuqhelekileyo kwenzeka kubantu abadala, abane‑ulusu olukhanyayo kunye nembali yomonakalo welanga. Ngelixa ukususa ngotyando kusetyenziswa utyando lwe‑Mohs micrographic, lolona nyango luqhelekileyo, kukho iindlela ezahlukeneyo zonyango ezifumanekayo.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) lithumba elisezantsi eliqala kumadlala athile esikhumbeni kwaye likhangeleka lifana ne-squamous cell carcinoma (SCC) phantsi kwemakroskopu. Kukho ingxoxo eqhubayo malunga nokuba i-KA kufuneka ihlelwe njengohlobo lwe-SCC ehlaselayo.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) lolona hlobo lwesibini luxhaphakileyo lomhlaza ebantwini, ngakumbi kubantu abadala. Utyando luhlala lusetyenziselwa ukunyanga i-cSCC, kodwa kwezinye izigulana ezingakwazi ukwenza utyando okanye ezikhetha ukungawenzi, iindlela ezinjengonyango lwe‑intralesional zingaqwalaselwa. Unyango lwesintu lwe‑intralesional (methotrexate or 5-fluorouracil) lusetyenzisiwe, kodwa kukho uphando oluqhubekayo kwiindlela ezintsha ezifana ne‑intralesional immunotherapy kunye ne‑oncolytic virotherapy. Apha, siza kujonga iindlela ezahlukeneyo zo nyango lwe‑intralesional ye‑cSCC, ukusuka kwiindlela zakudala ukuya kwezona ziphambili.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Phantsi kwemakroskopu, i‑keratoacanthoma (keratoacanthoma) ifana kakhulu ne‑squamous cell carcinoma. Ngelixa abanye i‑pathologists babona i‑keratoacanthoma (keratoacanthoma) njengento ecacileyo engengomdlavuza, malunga ne‑6 % yeekliniki kunye ne‑histological i‑keratoacanthoma (keratoacanthoma) ibonisa inkqubela kwi‑invasive and aggressive squamous cell cancers.
○ Uxilongo kunye noNyango
#Dermoscopy
#Skin biopsy